The introduction of the HPV vaccine in 2006 has resulted in a notable decline in cervical precancer cases among women aged 20 to 24. A CDC study revealed a 79% decrease in the overall incidence and an 80% reduction in higher-grade precancers from 2008 to 2022. This cohort represents the first group vaccinated at the recommended age, prior to sexual activity. Gardasil-9, the vaccine used in the U.S., protects against nine HPV types, drastically decreasing the risk of multiple cancers. Despite this success, the American Cancer Association forecasts over 13,000 new cervical cancer cases by 2025, highlighting ongoing concerns.
In a recent study from the CDC, cervical precancer incidence in women ages 20-24 saw a dramatic decrease by 79%, showing the effectiveness of the HPV vaccine.
The Gardasil-9 vaccine protects against nine types of HPV, significantly reducing the risk of various cancers, including cervical, in those vaccinated at a young age.
Collection
[
|
...
]